Showing 850 results
-
Media Release /- Kisqali is now the only CDK4/6 inhibitor indicated in combination with an aromatase inhibitor as first-line treatment for pre-, peri- or postmenopausal women with HR+/HER2- advanced breast cancer…
-
Media Release /- Galaxies of Hope offers a unique digital experience that engages users through the art of visual storytelling to connect with others to understand NET cancer - Using real-life stories and voices…
-
Media Release /- Voluntary recall and notice of corrective action issued after discovering certain blister card packages distributed in the U.S. do not meet U.S. child-resistant packaging requirements- Certain lots…
-
Media Release /- There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS), a highly debilitating form of MS characterized by gradual, irreversible worsening of…
-
Media Release /- Generation S offers the sickle cell community a powerful new way to share personal experiences and rewrite the story of an often-misunderstood disease- Singer-songwriter and actress Jordin Sparks…
-
Media Release /- The PARADIGMS study was the basis for the US Food and Drug Administration (FDA) approval of Gilenya (fingolimod) in May 2018 for pediatric patients (aged 10 to 17) with relapsing multiple sclerosis…
-
Media Release /- Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept- Superior reductions in central…
-
Media Release /New data show that 73% of ankylosing spondylitis (AS) patients taking Cosentyx® (secukinumab) achieved improvement in AS signs and symptoms at four years, with sustained ASAS response rates1 AS is a…
-
Media Release /- Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis,…
-
Media Release /Entresto® (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in an established biomarker…
